Most Feared Disease

Cracking The Code To Society’s Most Feared Disease

As a result, a disease-modifying treat-
ment for Alzheimer’s disease has become
a Holy Grail of sorts in the biotech indus-
try. The disease is so ubiquitous, it casts a
shadow over just about everyone’s family.
At the same time, it exacts a devastating
financial toll on society—perhaps even
greater than cancer—with Alzheimer’s
disease. In fact, some remarkable results
have been achieved in preclinical trials,
including one where the treated rodents
regained substantial functionality in
their legs after sustaining severe spinal
cord damage.

The estimated cost for caring for
Americans with Alzheimer’s disease and
other dementias is well in excess
of a quarter of a trillion dollars per an-
um. This doesn’t even include unpaid
caregiving. Also, Alzheimer’s disease is
ranked as the third leading cause of
death of seniors in the United States, sur-
passed only by heart disease and cancer.
Approximately 6 million Americans have
become its victims, and this number rises
each year as lifespans increase due to ad-
vanced medical science.

Progress From Pharmaceuticals

Fortunately, a few pharmaceuti-
cal companies, including Biogen, AC
Immune SA and NervGen Pharma, have come up with ways to potentially
treat the condition and perhaps slow it
down. NervGen’s medical researchers are
working on what may become an
important breakthrough for Alzheimer’s and other afflictions that are defined by
damage.

Could This Be Modern Medicine’s Holy Grail?

Until recently, NervGen’s focus has mostly been on developing nerve regen-
eration for the treatment of spinal cord injuries. In fact, some remarkable results
have been achieved in preclinical trials, including one where the treated rodents
regained substantial functionality in
their legs after sustaining severe spinal
cord damage.

Assuming it also works in humans,
the medical science world will be paying
very close attention because there are no
known therapies that can stimulate hu-
man nerve regeneration now.

In addition, NervGen intends to
commence a Phase 2 clinical trial for
treating multiple sclerosis. The compa-
y’s drug candidate is expected to treat
many of such debilitating symptoms as
numbness, loss of sensation, chronic and
deilitating pain, partial loss of move-
ment, paralysis, and even incontinence
due to additional mechanisms of action
called “remyelination” and “plasticity.”

The essence of this technology is that
it unlocks a damaged nervous system’s
natural ability to repair itself. Proprietary
molecules “unstick” nerves and prevent
new ones from getting stuck by in-
terfering with synaptic-like connections so
the nerves can regrow in places that are
normally highly inhibited by scar tissue.
The co-inventor of NervGen’s tech-
ology, Dr. Jerry Silver, is one of the
world’s most foremost neuroscience re-
searchers of spinal cord injury. Dr. Silver,
who is also Professor of Neurosciences at
Cleveland’s Case Western Reserve Uni-
versity’s School of Medicine, has been
working this unique approach to nerve
rejuvenation biotechnology since the early ’90s by focusing on a protein called
cSPG that inhibits the body’s natural
ability to grow and regenerate.

Herefore, no drugs have been ap-
proved anywhere in the world for nerve regeneration and remyelination, as
well as improved plasticity in damaged
nerves. Additionally, existing treatments
are not considered very effective. So, the
stakes are especially high for NervGen
to create a blockbuster drug candidate
that promises to even outshine any oth-
er Alzheimer’s disease drug. This is a
wonderful opportunity to pioneer nerve
repairing drug therapies that target
some of the most devastating and per-
vasive diseases known to humankind.

Learn More

For further facts and figures about
NervGen Pharma, go to www.nervgen.
com.